Long-term Follow-up Study of BHC001 for TDT

Long-term Follow-up Study of BHC001 in the Treatment of Transfusion-dependent β-thalassemia

Observe long-term safety risk and long-term efficacy after intravenous infusion of BHC001 in TDT subjects.

Observe long-term delayed safety risks such as emerging neoplasms, emerging haematological disorders, and long-term efficacy after intravenous infusion of BHC001 in TDT subjects.

Inclusion Criteria:

1. Provision of written informed consent for this study by subjects, or as applicable, subject's parent(s)/legal guardian(s)
2. Treated with BRL-101 for therapy of transfusion-dependent β-thalassemia.

Exclusion Criteria:

- There are no exclusion criteria for this study